Although cobalamin (vitamin B 12 ) deficiency was described over a century ago, it is still difficult to establish the correct diagnosis and prescribe the right treatment. Symptoms related to vitamin B 12 deficiency may be diverse and vary from neurologic to psychiatric. A number of individuals with vitamin B 12 deficiency may present with the classic megaloblastic anemia.
S
everal scientific articles and textbooks have described the clinical presentation of patients with cobalamin (vitamin B 12 ) deficiency. 1, 2 After the classic presentation of Addison-Biermer disease with megaloblastic anemia, many generations of doctors have been educated with the view that vitamin B 12 deficiency exclusively presents itself with this type of anemia. Additional cases have been reported in which neurologic abnormalities were the main presenting symptom, with subacute combined degeneration of the spinal cord as one of the most feared manifestations, 3 often leading to permanent disability. Lindenbaum et al 4 reported a large series of 40 patients who had neurologic symptoms or psychiatric disorders caused by vitamin B 12 deficiency but who had no anemia or macrocytosis. Psychiatric symptoms may vary from depression to mania, psychosis, and occasionally suicidal thoughts (Supplemental Table 1 , available online at http://mcpiqojournal.org). 5 The reason why some patients mainly present with megaloblastic anemia and others with neurologic symptoms remains unknown.
Laboratory investigations with the establishment of low serum B 12 levels and elevated levels of methylmalonic acid (MMA) are the cornerstone of diagnostics, but normal levels of serum B 12 and MMA do not exclude symptomatic B 12 deficiency. In clinical practice, many cases of B 12 deficiency are overlooked or sometimes even misdiagnosed because of misconceptions and misbeliefs among health care professionals. We have summarized the most frequently encountered misconceptions and misbeliefs regarding vitamin B 12 deficiency in Table 1 .
In this review, we discuss a number of typical patients who were seen at our outpatient clinic, and we summarize the possible clinical signs and symptoms of patients with vitamin B 12 deficiency and the pitfalls of diagnosis and treatment.
CASE DESCRIPTIONS
Patient A Patient A is a 55-year-old woman admitted to the psychiatry department of our hospital because of depression. In addition to symptoms related to her depression, she reported pain in the lower legs, paresthesia and numbness in the feet, and difficulty walking. Her history included Graves disease, for which she had undergone thyroidectomy several years earlier and was subsequently prescribed levothyroxine. We were invited for consultation because of slightly elevated free thyroxine levels. The patient had no symptoms suggestive of thyrotoxicosis. On examination, she had signs of severe peripheral neuropathy of the lower legs (absent reflexes, superficial and deep sensation) and several skin lesions compatible with vitiligo. Laboratory studies (also summarized in Supplemental Table 2 , available online at http://mcpiqojournal.org) (reference ranges provided parenthetically) revealed a hemoglobin level of 7.0 mmol/L (>7.5 mmol/L) and mean corpuscular volume of 105 fl (85-98 fl). Her serum vitamin B 12 level was 51 pmol/L (145-450 pmol/L). These findings prompted the diagnosis of pernicious anemia caused by vitamin B 12 deficiency, and hydroxocobalamin injections were initiated immediately. Within 3 to 4 weeks, the patient reported that her symptoms gradually lessened, and her walking capacity improved. Additional laboratory tests revealed the presence of antibodies against parietal cells and intrinsic factor (IF). Six weeks later, the attending psychiatric resident ordered an additional serum vitamin B 12 measurement. Because the serum vitamin B 12 level was greater than 1476 pmol/L, hydroxocobalamin injections were stopped after consultation with an internal medicine resident. The patient was discharged home 3 months later, but no follow-up appointment at our outpatient clinic was made. The discharge letter did not mention the diagnosis of pernicious anemia, nor the treatment with hydroxocobalamin injections. This exclusion went unnoticed until 8 months later, when we realized she was lost to follow-up and invited her for a follow-up visit. She presented at our outpatient clinic shortly thereafter and reported a severe increase of her symptoms. One month earlier, her primary care physician had ordered measurement of her serum vitamin B 12 level, which was 251 pmol/L; he did not restart treatment because he was unaware of the earlier findings. We strongly advised the patient to recommence hydroxocobalamin injections, which she continued twice weekly for the following 2 years. Gradually, her symptoms abated. Two years later, there were still bouts of pain, numbness, and paresthesia, but she was able to walk supported only by a walking stick. This case is a clear example of pernicious anemia in the constellation of a polyglandular autoimmune syndrome. Unwarranted cessation of therapy may lead to severe worsening of neurologic abnormalities and irreversible damage.
Patient B
Patient B is a 17-year-old girl who had a 2-year history of fatigue, sleepiness, numbness in her hands, dizziness, exertional dyspnea, and 11e14 Although the demonstration of low serum vitamin B 12 levels is considered diagnostic, there is a poor correlation between these levels and symptoms, 8, 9, 15 and even people with vitamin B 12 levels below 140 pmol/L may not have symptoms. 16 This factor sheds a different light on the discussion regarding appropriate cutoff levels for serum vitamin B 12 and related parameters. Some investigators suggest that it is necessary to establish different reference cutoffs according to age and the applied analytic method. 17 However, serum vitamin B 12 tests also may fail because many people with symptoms related to cobalamin deficiency may have serum vitamin B 12 levels above the lower reference level of 140 pmol/L. 18, 19 Although several factors may be of influence, in a considerable number of cases this issue can be caused by the earlier use of oral supplementation with multivitamins or high-dose oral vitamin B 12 preparations. 20 It has been reported that even a dose of 10 mg/d can increase vitamin B 12 levels to more than 200 pmol/L in elderly individuals (>65 years). 21 Oral supplementation may increase the serum vitamin B 12 level but often not enough to replenish the vitamin B 12 levels in the tissues 21 unless very high doses (1000-2000 mg/d) are used.
BIOCHEMISTRY AND DIAGNOSIS
Vitamin B 12 deficiency may be easily overlooked in patients when only total serum vitamin B 12 is used as a status marker. 18,22e25 Many investigators therefore advocate measuring one or both of the additional functional biomarkers MMA and homocysteine to establish vitamin B 12 deficiency. Especially in people with so-called borderline vitamin B 12 levels, ie, those between 140 and 300 pmol/L, elevated MMA and/or homocysteine values may aid in establishing a possible diagnosis of deficiency. 18, 26, 27 The mechanism by which these biomarkers may demonstrate cobalamin deficiency can be derived from the role of vitamin B 12 in our body. Vitamin B 12 is a pivotal cofactor in 2 enzymatic reactions. Its deficiency will impair the proper function of these enzymes and lead to accumulation of the substrate. Methylmalonylecoenzyme A (CoA) mutase, which catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA, is one of the vitamin B 12 edependent enzymes, and impaired function will cause elevations of methylmalonyl-CoA and thereby MMA after cleavage of CoA. The other vitamin B 12 edependent enzyme is methionine synthase, which regenerates methionine from homocysteine, and impaired activity as the consequence of vitamin B 12 deficiency will lead to accumulation of homocysteine. 28, 29 From this process, it can be understood how low tissue levels of cobalamin will increase MMA and homocysteine, and a clear relationship between serum vitamin B 12 , MMA, and homocysteine has been described in the National Health and Nutrition Examination Survey population. 29 Nevertheless, the sensitivity and specificity of elevated MMA and/or homocysteine levels in patients with symptoms associated with vitamin B 12 deficiency are unknown. Also, it has been documented that MMA levels are elevated in people with severely impaired renal function. 30 Similarly, elevated homocysteine values can also be the consequence of folate or vitamin B 6 deficiency, as well as impaired renal function, hypothyroidism, and certain medications. 6 In a separate study, we calculated from the National Health and Nutrition Examination Survey and Lifelines epidemiological studies that MMA and/ or homocysteine levels are elevated above current reference values (>300 nmol/L and 10 mmol/L, respectively) in only 73% of people with low serum vitamin B 12 44e47 and it has been reported that assays fail to measure low total vitamin B 12 concentrations in some samples because of an unknown artifact. 48 Carmel and Agrawal 48 reported that in 25% of patients with pernicious anemia, the assay may have produced false-normal values. We strongly believe that our patient E fits the description of interfering anti-IF antibodies. She had overt macrocytic anemia, initially diagnosed as myelodysplastic syndrome. Repeated serum vitamin B 12 measurements yielded normal results, and in the following 3 years, she had development of symptoms compatible with severe polyneuropathy and nerve damage, signs of subacute combined degeneration of the spinal cord. After both MMA and homocysteine levels were found to be grossly elevated, it was realized that she had severe vitamin B 12 deficiency. An additional factor that may have added to her protracted course was that she had been treated with high doses of folate. It is well known that folate therapy may mask anemia, and not treating with cobalamin may accelerate neurologic damage in people with vitamin B 12 deficiency. 49 
POSSIBLE CAUSES OF VITAMIN B 12 DEFICIENCY
The polyglandular autoimmune syndrome is easily recognizable as a cause of deficiency in patients A and E. Polyglandular autoimmune syndromes are characterized by a number of (endocrine) diseases in which autoantibodies directed against certain organs or cell constituents can be demonstrated in the blood.
50e53 Table 3 summarizes the most prevalent disorders, varying from autoimmune thyroid disease (Hashimoto or Graves disease) to type 1 diabetes, Addison disease, and vitiligo. In the situation of vitamin B 12 deficiency, both antibodies against IF and antibodies against parietal cells can be found, although it must be realized that the sensitivity of these measurements is low. One study found that only 55% of people of Western European descent with documented pernicious anemia had anti-IF antibodies. 54 However, this was not a very recent study, and methodology to demonstrate antibodies may have changed. Studies that assessed different assays to measure anti-IF antibodies have yielded discrepant results.
54e56 Conversely, some investigators have argued that testing for gastric parietal cell antibodies is an appropriate screening test for pernicious anemia. 57 Other causes that can lead to vitamin B 12 deficiency are summarized in Supplemental Table 3 (available online at http:// 63 Finally, a new group of vitamin B 12 edeficient individuals is rapidly developing as the number of people undergoing bariatric surgery worldwide is increasing. 64, 65 Bariatric surgery has become one of the major treatments for (morbid) obesity, and reduced production of both IF and gastric acid, as well as reduced intake of vitamin B 12 econtaining foods, contribute to the development of vitamin B 12 deficiency (patient F). A recent study from The Netherlands reported a 60% incidence of postebariatric surgery vitamin B 12 deficiency, defined as a serum MMA level greater than 300 pmol/L. 66 Interestingly, these investigators also reported that positive results of parenteral vitamin B 12 administration were reported by patients without functional vitamin B 12 deficiency (MMA <300 nmol/L), suggesting that supplementation itself, regardless of the actual vitamin B 12 status, improves clinical symptoms. 66 Finally, severe cases of vitamin B 12 deficiency have been reported in young individuals using nitrous oxide as a recreational drug.
67e69

FAMILIAL/GENETIC CAUSES OF VITAMIN B 12 DEFICIENCY
The literature on familial cases of vitamin B 12 deficiency is limited. Classically, the Imerslund-Gräsbeck syndrome is mentioned as an example of a genetic cause of vitamin B 12 deficiency due to selective malabsorption, but its prevalence is very low. Other causes may be mutations in the gene for intrinsic factor, 70 genes encoding the vitamin B 12 transporting transcobalamins, 71, 72 and genes involving intracellular vitamin B 12 metabolism. The list of single-nucleotide polymorphisms associated with serum vitamin B 12 concentration is gradually increasing, and a recent review reported 59 gene polymorphisms found in a wide variety of populations, although the majority were reported in people of Western European descent. 37 Recent studies have found an association between homozygosity of the TT methylenetetrahydrofolate reductase C677T genotype and vitamin B 12 deficiency. 73e75 In the near future, dedicated evaluation of genetic mutations in genes that are associated with vitamin B 12 metabolism, for instance with whole-exome sequencing, may shed light on familial cases.
CONSEQUENCES OF MATERNAL AND IN-FANT LOW B 12 STATUS
Maternal vitamin B 12 deficiency during pregnancy may be associated with an increased incidence of neural tube defects and brain development retardation, 76 as well as preterm birth and low birth weight. 77 Wnt signaling has been reported to be disrupted in the developing cerebellum of the offspring of vitamin B 12 e and folate-deficient female rats 78 and is associated with long-term disabilities of behavior and memory. 79 Ethnic differences in vitamin B 12 levels have been observed in pregnancy, possibly related to differences in intake of animal-derived foods. 80 Children born to mothers with normal to high folate levels and low serum vitamin B 12 values have higher truncal adiposity and insulin resistance, 81 which may influence long-term risk of development of type 2 diabetes and cardiovascular disease. 82, 83 Insufficient vitamin B 12 status has an important negative influence on children's development and cognitive functioning. 84, 85 Nutritional vitamin B 12 deficiency in children, and a late diagnosis of this condition, may lead to irreversible neurologic damage such as growth and motor retardation and even convulsions, 86 and recent studies indicate a relationship between maternal vitamin B 12 status and bone mass in the offspring. 87 Disturbed vitamin B 12 status as well as (maternal) genetic factors may influence DNA methylation patterns in the newborn and thereby predispose individuals to specific disease later in life. 88 NATURAL COURSE OF VITAMIN B 12 DEFICIENCY Importantly, the natural course of vitamin B 12 deficiency is not clearly understood. In typical patients, in whom clear signs and symptoms associated with (poly)neuropathy and/or megaloblastic anemia are explained by the unequivocal finding of low serum vitamin B 12 levels, like in patient A, it is not particularly difficult to make a diagnosis and institute treatment. However, more widespread screening for vitamin B 12 deficiency may result in situations in which low serum vitamin B 12 levels are found but without clear symptomatology. 10 Parenteral vitamin B 12 administration is also useddaccording to the package insertdfor the prevention of vitamin B 12 eassociated problems. In some individuals without symptoms, low levels of serum vitamin B 12 may be associated with reductions in the binding protein haptocorrin. 89 However, this condition may be difficult to discriminate from true vitamin B 12 deficiency in the presence of symptoms, as is evidenced by patient B.
JUST A VITAMIN, OR MORE?
Some of the cases reported in this article, as well as the study by Smelt et al 66 mentioned previously, suggest that supplementation of vitamin B 12 itself, regardless of the actual vitamin B 12 status, improves clinical symptoms. This hypothesis may put our thinking on the pathophysiology of vitamin B 12 deficiency in a different perspective. Maybe we should not regard vitamin B 12 as a vitamin that needs to be restored to normal levels to ensure proper functioning of metabolic pathways but rather as a general nerve-protecting and nerve-regenerating compound. There are some clues in the medical literature that support this concept. Cobalamin may regulate the balance between neurotoxic and neurotrophic agents. 90, 91 Micronutrients including vitamin B 12 might improve the neuropathy score in patients with type 2 diabetes, 92 but in this study, a mixture of nutrients was used, including multivitamins and vitamin B 12 orally. Another study reported that parenteral vitamin B 12 administration was more effective than nortriptyline in the treatment of painful diabetic neuropathy. 93 A 2005 meta-analysis 94 reported that a high-dose oral cyanocobalamin or methylcobalamin had beneficial effects on symptoms of diabetic neuropathy, such as pain and paresthesia. In 3 studies, methylcobalamin therapy also improved autonomic symptoms. Effects on vibration perception and electrophysiologic measures were not consistent. However, one review did not find any evidence that the use of oral vitamin B 12 supplements is associated with improvement in the clinical symptoms of diabetic neuropathy. 95 Low central nervous system cobalamin levels may play a role in the development of multiple sclerosis. 96, 97 Similar observations, and even reports on beneficial effects of vitamin B 12 injection therapy, have been reported in patients with myalgic encephalomyelitis, with and without fibromyalgia. 98, 99 Also, there are clues that low vitamin B 12 status is related to the development of chemotherapy-induced peripheral neuropathy. 100 Prospective studies to assess whether vitamin B 12 supplementation may prevent chemotherapy-induced peripheral neuropathy are planned or ongoing. 101 A recent intriguing study comes from US investigators, who demonstrated low vitamin B 12 levels in the brain tissue of aged individuals, especially those older than 60 years, and of people with autism and schizophrenia. 102 They speculate that on one hand vitamin B 12 status in the brain compartment is distinctly regulated during aging from the rest of the body, while on the other hand may contribute to impaired brain function and in the etiology of neurologic disorders. These observations are supported by a recent study that reported improvement of symptoms in children with autism spectrum disorder treated with frequent hydroxocobalamin injections. 103 Finally, in a prospective study, Brito et al 104 found that one injection of high-dose (10 mg) cyanocobalamin, pyridoxine, and thiamine increased several metabolic markers of mitochondrial function oxidative stress, nerve function, and myelin integrity such as acylcarnitines, plasmalogens, phospholipids, and sphingomyelins.
HOW SHOULD TREATMENT BE GIVEN?
Traditionally, vitamin B 12 is administered by intramuscular (IM) injection because of the low degree of resorption after oral administration as a consequence of the underlying disease. For parenteral therapy in cases of megaloblastic anemia, it has been advised to administer 1000 mg hydroxocobalamin IM twice weekly for a period of 5 weeks, and the dose is reduced to 1000 mg IM every 2 months thereafter. In the United States, often cyanocobalamin is used. 10, 15 In case of neurologic symptoms or abnormalities, it is suggested to administer hydroxocobalamin, 1000 mg once or twice weekly for a period of up to 2 years, and the package insert for hydroxocobalamin has included these particular instructions for several decades. However, it is ill defined which neurologic symptoms or abnormalities require such intensive treatment. Clinical practice has shown that in a substantial number of patients seen in a tertiary care setting, injection frequency cannot be reduced after the initial loading regimen. This topic has gained much interest recently, and studies evaluating this phenomenon are ongoing. 105 Since the 1990s, interest in the possibilities of oral instead of parenteral administration has emerged. In 2014, a Dutch Viewpoint on Vitamin B 12 Treatment was presented by the Dutch Organization of General Practitioners. 106 Motivation to publish this Viewpoint was the observed increase in serum vitamin B 12 testing and findings of abnormal test results. In this Viewpoint, it was stated that oral vitamin B 12 administration was preferred over parenteral supplementation. This advice has been based on a very limited number of clinical trials. A 2005 Cochrane review evaluated 2 randomized controlled trials comprising a total of 108 participants and suggested that oral vitamin B 12 may be as effective as IM administration in obtaining short-term hematologic and neurologic responses in vitamin B 12 edeficient patients. 107 The first study by Kuzminski et al 108 was performed in 33 vitamin B 12 edeficient patients, the majority with atrophic gastritic or pernicious anemia, and reported that serum vitamin B 12 levels were significantly higher and MMA levels significantly lower in the oral group (n¼18) compared to the IM group (n¼15). Similar numbers of patients reported improvement (n¼2) or clearance of symptoms (n¼2) in both groups. Typically in patients using vitamin B 12 injections, serum vitamin B 12 levels exceed the upper limit of normal (1476 pmol/L), and this finding suggests that there may be underdosing in the injection group. Patients were randomized to receive 2000 mg of oral cyanocobalamin administered with breakfast daily for 4 months or 1000 mg of cyanocobalamin administered IM with increasing intervals. Evaluation was at 4 months, when the oral group was still using supplementation but the IM group had received the most recent injection 1 month earlier. In addition, parenteral administration consisted of cyanocobalamin, not hydroxocobalamin, and it has been reported that hydroxocobalamin has a longer retention in plasma and a lower excretion in urine than an equivalent dose of cyanocobalamin. 109 A second study performed in Turkey 110 included 70 patients with megaloblastic anemia. In 8 of 24 participants in the oral group, vitamin B 12 deficiency was caused by poor nutrition. Ten patients were excluded because they did not appear for follow-up, and it should be noted that these patients were mainly randomized to the oral supplementation group. Research into the etiology of vitamin B 12 deficiency was rather poor. Only 19 patients had antieparietal cell antibodies assessed, which was due to costs as stated by the authors. Finally, the prevalence of neurologic symptoms was low. Only 7 of 60 participants reported altered cognitive function. Taken together, the articles provide very weak support for oral rather than parenteral vitamin B 12 administration, and the large number of participants in the study by Bolaman et al 110 with an etiology of poor nutrition (and not malabsorption) strongly biases these results in favor of simple oral vitamin B 12 administration, which is the default in any nutritional insufficiency of vitamin B 12 including vegetarianism. However, dosage is important in this respect. A study by Hill et al 21 found that supplementation with 500 mg of cyanocobalamin did not normalize moderately elevated MMA levels in healthy elderly people (aged 65 years or older). A recent Cochrane review confirmed that there is only very low-quality evidence that oral vitamin B 12 appears as safe as IM vitamin B 12 . 111 The authors concluded that further trials should conduct better randomization and blinding procedures, recruit more participants, provide adequate reporting, and measure important outcomes such as the clinical signs and symptoms of vitamin B 12 deficiency, health-related quality of life, socioeconomic effects, and adverse events adequately. 111 Serious adverse effects, even with high doses of hydroxocobalamin, have never been reported. 112, 113 However, some patients do report acneiform eruptions or rosacea. 114 
POSSIBLE PLACEBO EFFECTS UNLIKELY
In discussions on the effect of hydroxocobalamin treatment, often the suggestion is made that part of the effect is that of a placebo. Indeed, there is evidence that placebo treatments can have large and sustained effects on clinical outcomes in multiple disorders, as reviewed by Ashar et al, 115 who suggested that this effect may be particularly prominent in disorders in which emotion and motivation play a central role. In vitamin B 12 deficiency, there is no evidence that recovery of megaloblastic anemia or normalization of elevated MMA levels as a consequence of hydroxocobalamin injections can be regarded as a placebo effect. Yet, when patients' neurologic or cognitive symptoms improve by injection therapy, it is often ascribed to a placebo effect. Several studies have assessed the effects of oral vitamin B 12 supplementation in a variety of disorders, usually in people with normal serum vitamin B 12 levels, 116, 117 with a surprising benefit in, for example, aphthous stomatitis. 118 We have not found many well-designed studies of hydroxocobalamin injections in patients with neurologic symptoms caused by vitamin B 12 deficiency. One study reported favorable effects of hydroxocobalamin injections in patients with mechanical or irritative lumbago, 119 whereas another well-designed study reported improvement of symptoms in children with autism spectrum disorder. 103 Clearly, there is a need for well-conducted double-blind, randomized studies in patients with vitamin B 12 deficiency who report the benefit of continued frequent (twice weekly) hydroxocobalamin injections vs oral supplementation.
CONCLUSION
The spectrum of symptoms and signs suggestive of vitamin B 12 deficiency is reasonably well defined. Nevertheless, many of the symptoms are nonspecific and may occur as a consequence of other diseases. Currently, no research has documented the positive and negative predictive values of specific symptoms or symptom scores for the presence of vitamin B 12 deficiency.
Patients with low serum vitamin B 12 levels may have no symptoms (yet). Nevertheless, they are at high risk for development of symptoms. There is a tendency among physicians to consider a serum vitamin B 12 level higher than 140 pmol/L as normal, but many symptomatic patients may present with such levels, for instance because of taking oral vitamin supplementation. This does not mean that their tissue vitamin B 12 levels are normal as well. Methylmalonic acid and homocysteine are not very sensitive biomarkers, but there is currently no good alternative, although systematic evaluation of more advanced metabolic factors may lead to the application of better biomarkers. When serum total vitamin B 12 levels are low or questionable, the combination of total vitamin B 12 , active vitamin B 12 , MMA, and homocysteine may be the best strategy, but the validity of this combined biomarker approach 43 needs to be validated in larger prospective studies and especially validated against objective markers of treatment response. In case of doubt, when results of biomarker measurements are equivocal, a trial with parenteral hydroxocobalamin injections may be considered, as was done in patients B and D. Because symptom improvement in long-standing (subclinical) vitamin B 12 deficiency may take some time, we usually advise a treatment regimen of twice weekly hydroxocobalamin injections for 3 months, after which a thorough reevaluation is performed with systematic evaluation of symptom score as demonstrated in patient B (Table 2 ). There is no proof in large prospective, double-blind studies that oral supplementation is as effective in reducing symptoms associated
